Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEPU-AKI in Hemorrhagic Shock Patients
NCT06531642Phase 3Recruiting
- Sponsor
- UTHealth Houston
- Start
- Sep 2024
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of pantoprazole in acute kidney injury (AKI) (2 arms), sponsored by UTHealth Houston. Primary endpoint: Urinary Kidney Biomarker Levels at 48 hours. Started Sep 2024; status: recruiting.
02
Drugs
pantoprazole
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT06531642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06531642.